The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory ...
Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure ...
An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that ...
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims ...
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen ...
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ...
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed ...
Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer ...
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results